

For Immediate Release

Q4 Net Revenue grew 18% to Rs 740 Crores, Net Profit at Rs 94 cr

Vadodara May 3rd, 2017

Alembic Pharmaceuticals Limited reported its consolidated financial results for the fourth quarter ending 31st March 2017.

Financial Highlights

- Net Sales for the quarter up 18% to Rs 740 crores
- Net Profit for the quarter at Rs 94 crores against Rs 92 crores last year.
- FY17 Net sales at Rs 3131 crores as against Rs 3162 crores last year.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said

“We have closed out very good year where our facilities remain in compliance and we continue to invest for the future. We spent Rs 427 crore on R&D and filed 20 ANDA applications.”

Operational Highlights

International Business

- International formulation business grew 44% to Rs 273 crores for the quarter
- US Business grew 54% to Rs 200 crores for the quarter
- Bioequivalence facility successfully audited by the US FDA without any observations
- 4 ANDA approvals received during the year, Cumulative ANDA approvals at 52
- Highest ever 10 ANDA filings during the quarter and 20 ANDA filings for FY17
- Cumulative ANDA filings at 95
- FY17 R&D spend at Rs 427 Crores, approximately 14% of Sales.

India Formulations Business

- India formulations business for the quarter at Rs 286 crores as against Rs 269 crores last year
- India formulations business for the year at Rs 1255 crores as against Rs 1176 crores last year



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123

Dividend

- The Board has recommended dividend on equity shares at Rs 4.00 per share i.e. 200% for 16-17 (P.Y. Rs 4.00 per share i.e. 200%)

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q4 FY17	Q4 FY16	FY17	FY16
Formulation				
International	273	190	1236	1461
India	286	269	1255	1176
API	181	167	640	525
Total	740	626	3131	3162

The Profit break-up is as under:

(Rs in Crores)

Particulars	Q4 FY17	Q4 FY16	FY17	FY16
EBITDA Pre R&D	244	254	1029	1313
<i>EBITDA Pre R&D %</i>	<i>33%</i>	<i>41%</i>	<i>33%</i>	<i>42%</i>
EBITDA Post R&D	135	143	615	1007
<i>EBITDA Post R&D %</i>	<i>18%</i>	<i>23%</i>	<i>20%</i>	<i>32%</i>
Profit Before Tax	112	120	529	936
Net Profit after Tax	94	92	401	720

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123



Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 – 306 11681	Phone: +91 265 – 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123